Prospective, open study of long-acting injected risperidone versus oral antipsychotics in 88 chronically psychotic Patients

Pharmacopsychiatry

Volumn 43, Issue 2, 2010, Pages 66-72

  Girardi, P ^a   Serafini, G ^a   Pompili, M ^a,b   Innamorati, M ^c   Tatarelli, R ^a   Baldessarini, R J ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; RISPERIDONE;

ADULT; AGED; AKATHISIA; ARTICLE; BRADYKINESIA; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; DYSLIPIDEMIA; DYSTONIA; FATTY LIVER; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; HYPERPROLACTINEMIA; HYPERTENSION; HYPOTENSION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; ORTHOSTATIC HYPOTENSION; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PSYCHOSIS; SIDE EFFECT; TREATMENT DURATION; TREMOR; URIC ACID BLOOD LEVEL; VIRILIZATION; WEIGHT GAIN;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIPSYCHOTIC AGENTS; CARBOHYDRATES; CHRONIC DISEASE; DELAYED-ACTION PREPARATIONS; FEMALE; FOLLOW-UP STUDIES; HOSPITALIZATION; HUMANS; INJECTIONS; MALE; MICROSPHERES; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; RISPERIDONE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77949886589     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0029-1239541     Document Type: Article

References (67)

1. Adams CE, Fenton MK, Quraishi S et al. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001 179 290-299
2. Adler AI, Stratton IM, Neil HA et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): Prospective observational study. BMJ 2000 32 412-419
3. Altamura AC, Sassella F, Santini A et al. Intramuscular preparations of antipsychotics: Uses and relevance in clinical practice. Drugs 2003 63 493-512
4. Bai YM, Chen TT, Wu B et al. A comparative efficacy and safety study of long-acting risperidone injection and risperidone oral tablets among hospitalized patients: 12-week randomized, single-blind study. Pharmacopsychiatry 2006 39 135-141
5. Baldessarini RJ. Enhancing treatment with psychotropic medicines. Bull Menninger Clin 1994 58 24-241
6. th edn., New York: McGraw-Hill Press 2005 461-500
7. Bhanji NH, Chouinard G, Margolese HC. Review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia. Eur Neuropsychopharmacol 2004 14 87-92
8. Bishara D, Taylor D. Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability. Drugs 2008 68 2269-2292
9. Bondolfi G, Baumann P, Dufour H. Treatment-resistant schizophrenia: clinical experience with new antipsychotics. Eur Neuropsychopharmacol 1996 6 (Suppl 2) S21-S25
10. Centorrino F, Cincotta SL, Talamo A et al. Hospital use of antipsychotic drugs: polytherapy. Compr Psychiatry 2008 49 65-69
11. Chue P, Eerdekens M, Augustyns I et al. Efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol 2005 15 111-117
12. Chue P, Eerdekens M, Augustyns I et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. European Neuropsychopharmacology 2005 15 111-117
13. Chung S, Cho SJ, Kim CH et al. Effectiveness and tolerability of long-acting risperidone: 12-weeks, multi-center switching study from oral antipsychotics. Korean J Psychopharmacol 2005 16 109-120
14. Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand 2002 106 286-290
15. Csernansky JG, Mahmoud R, Brenner R. Comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002 346 16-22
16. Davis JM, Matalon L, Watanabe MD et al. Depot antipsychotic drugs: place in therapy. Drugs 1994 47 741-773
17. Dolder C. Review: paliperidone reduces symptoms of schizophrenia and schizophrenia-like illness. Evid Based Ment Health 2008 11 114
18. Eerdekens M, Fleischhaker WW, Xie Y, Janssen Research Foundation et al. Long-term safety of long-acting risperidone microspheres. Schizophrenia Res 2002 53 (Suppl 3) S174
19. Edwards J, Maude D, Herrmann-Doig T et al. Service response to prolonged recovery in early psychosis. Psychiatr Serv 2002 53 1067-1069
20. Ereshefsky L, Mascarenas CA. Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J Clin Psychiatry 2003 64 (Suppl 16) S18-S23
21. Fleischhacker WW, Eerdekens M, Karcher K et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 2003 64 1250-1257
22. Gallagher D, Heymsfield SB, Heo M et al. Healthy percentage body fat ranges: an approach for developing guidelines based on body mass index. Am J Clin Nutr 2000 72 694-701
23. Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic agents: a critical overview. Can Med Assoc J 2005 172 1703-1711
24. Glazer WM, Kane JM. Depot neuroleptic therapy: An underutilized treatment option. J Clin Psychiatry 1992 53 426-433
25. Gorham DR, Overall JE, Sajatovic M et al. Brief Psychiatric Rating Scale (BPRS). Rating Scales in Mental Health 2001 Hudson, OH: Lexi-Comp Corp
26. Gross G, Huber G. Schizophrenia: neurodevelopmental disorder or degenerative brain process? Fortschr Neurol Psychiatr 2008 76 (Suppl 1) S57-S62
27. Groves JE, Mandel MR. Long-acting phenothiazines. Arch Gen Psychiatry 1975 32 893-900
28. Guy W. ECDEU Assessment Manual for Psychopharmacology Washington, DC: US Department of Health, Education, and Welfare 1976 218-222
29. Hogarty GE, Schooler NR, Ulrich R et al. Fluphenazine and social therapy in the aftercare of schizophrenic patients: Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Arch Gen Psychiatry 1979 36 1283-1294
30. Jones A. What are the nursing implications when using paliperidone prolonged release for people with schizophrenia. J Psychiatr Ment Health Nurs 2008 15 792-799
31. Kane JM. Review of treatments that can ameliorate nonadherence in patients with schizophrenia. J Clin Psychiatry 2006 67 (Suppl 5) S9-S14
32. Kane JM, Eerdekens M, Lindenmayer JP et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003 160 1125-1132
33. Kasper S. First-episode schizophrenia: the importance of early intervention and subjective tolerability. J Clin Psychiatry 1999 60 (Suppl 23) S5-S9
34. Keith S. Use of long-acting risperidone in psychiatric disorders: Focus on efficacy, safety and cost-effectiveness. Expert Rev Neurother 2009 9 9-31
35. Keith SJ, Pani L, Nick B et al. Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia. Psychiatr Serv 2004 55 997-1005
36. Keks NA, Ingham M, Khan A et al. Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Randomised, controlled, open-label study. Br J Psychiatry 2007 191 131-139
37. Lasser RA, Bossie CA, Gharabawi GM et al. Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trial. Int J Neuropsychopharmacol 2005 8 427-438
38. Lasser R, Bossie CA, Gharabawi G et al. Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder. J Affect Disord 2004 83 263-275
39. Lauriello J, McEvoy JP, Rodriguez S et al. Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia. Schizophrenia Res 2005 72 249-258
40. Lee MS, Ko YH, Lee SH et al. Long-term treatment with long-acting risperidone in Korean patients with schizophrenia. Hum Psychopharmacol 2006 21 399-407
41. Leucht S, Barnes TR, Kissling W et al. Relapse prevention in schizophrenia with new-generation antipsychotics: Systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003 160 1209-1222
42. Lewis S, Lieberman J. CATIE and CUtLASS: can we handle the truth? Br J Psychiatry 2008 192 161-163
43. Lieberman JA. Pathophysiologic mechanisms in the pathogenesis and clinical course of schizophrenia. J Clin Psychiatry 1999 60 (Suppl 12) S9-S12
44. Lieberman JA, Stroup TS, McEvoy JP, etal.,. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005 353 1209-1223
45. Lindenmayer JP, Eerdekens E, Berry SA et al. Safety and efficacy of long-acting risperidone in schizophrenia: A 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. J Clin Psychiatry 2004 65 1084-1089
46. Love RC. Strategies for increasing treatment compliance: the role of long-acting antipsychotics. Am J Health Syst Pharm 2002 (Suppl 8) S10-S15
47. Love RC, Conley RJ. Long-acting risperidone injection. Am J Health Syst Pharm 2004 61 1792-1800
48. Masand PS, Gupta S. Long-acting injectable antipsychotics in the elderly: Guidelines for effective use. Drugs Aging 2003 20 1099-1110
49. Masand PS, Narasimhan M. Improving adherence to antipsychotic pharmacotherapy. Curr Clin Pharmacol 2006 1 47-56
50. Möller HJ. Long-acting risperidone: focus on safety. Clin Ther 2006 28 633-651
51. Möller HJ, Llorca PM, Sacchetti E et al. Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Int Clin Psychopharmacol 2005 20 121-130
52. Nasrallah HA. The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr Scand 2007 115 260-267
53. Novick D, Bousono M, Suarez D et al. Use of concomitant medication with antipsychotic treatment in outpatients with schizophrenia: Results from the European Schizophrenia Outpatients Health Outcomes (SOHO) study. Prog Neuropsychopharmacol Biol Psychiatry 2005 29 972-982
54. Owens DC. What CATIE did: Some thoughts on implications deep and wide. Psychiatr Serv 2008 59 530-533
55. Rothbard AB, Kuno E, Roley K. Trends in the rate and type of antipsychotic medications prescribe to persons with schizophrenia. Schizophrenia Bull 2003 29 531-540
56. Schooler NR. Relapse and rehospitalization: Comparing oral and depot antipsychotics. J Clin Psychiatry 2003 64 (Suppl 16) S14-S17
57. Schooler NR, Levine J, Severe JB et al. Prevention of relapse in schizophrenia: Evaluation of fluphenazine decanoate. Arch Gen Psychiatry 1980 37 16-24
58. Sheehan DV, Lecrubier Y, Sheehan KH et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998 59 (Suppl 20) S22-S33
59. Simpson GM, Mahmoud RA, Lasser RA et al. A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 2006 67 1194-1203
60. Taylor DM, Fischetti C, Sparshatt A et al. Risperidone long-acting injection: prospective 3-year analysis of its use in clinical practice. J Clin Psychiatry 2009 70 196-200
61. Taylor DM, Young CL, Mace S et al. Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients. J Clin Psychiatry 2004 65 1076-1083
62. Taylor M, Currie A, Lloyd K et al. Impact of risperidone long acting injection on resource utilization in psychiatric secondary care. J Psychopharmacol 2008 22 128-131
63. Turner M, Eerdekens E, Jacko M et al. Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. Int Clin Psychopharmacol 2004 19 241-249
64. van Os J, Bossie CA, Lasser RA. Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone. Int Clin Psychopharmacol 2004 19 229-232
65. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36) I Conceptual framework and item selection. Med Care 1992 30 47-483
66. Young CL, Taylor DM. Health resource utilization associated with switching to risperidone long-acting injection. Acta Psychiatr Scand 2006 114 14-20
67. Young JL, Zonana HV, Shepler L. Medication noncompliance in schizophrenia: codification and update. Bull Am Acad Psychiatry Law 1986 14 105-122